ALK and non-small cell lung carcinoma: For cMET blockade, we used crizotinib, a small-molecule tyrosine kinase inhibitor that efficiently inhibits c-MET, anaplastic lymphoma kinase 5 (ALK5) and ROS1 and is approved by the FDA for treatment of ALK-rearranged NSCLC [4].